Treatment of Opioid Use Disorder: Waiver Qualifying - St. Louis, MO - Friday, November 08, 2019
-
Register
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Friday, November 08, 2019 | 8:00 am CT - 12:30 pm CT
Centene Corporation - Auditorium, First Floor
7700 Forsyth Boulevard
St. Louis, MO 63105
Online Portion Due: November 7, 2019
The curriculum for this course has been specifically designed for women's health providers.
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course.
In the content section you will find 2 different components for the live learning. For those attending live in-person, you can skip over the live webinar portion to complete the CME Evaluation and claim your CME Certificate.
For those attending Live-Via Webinar, you will have access to the "Live Webinar" component 30 minutes before the training. You will click on this link to access the webinar on the 29th.
Getting started: To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."
If you have any questions, please contact education@ASAM.org.
- Locate the box on the right that says “View Course" and click “View Course"
- A new window will open with the course. Be sure your pop-up blocker is turned off.
- Complete Module 1 and Module 2 (equivalent to four hours of instruction)
- You will be required to pass all CME Quizzes with a grade of 70% or higher
- Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center
Learning Objectives
Module 1
1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: December 2019
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.
The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Dan Alford, MD, MPH, DFASAM, Chair | None | ||
Alta DeRoo, MD, FASAM | None | ||
Edwin Salsitz, MD, DFASAM, Curriculum Director | None | ||
Soraya Azari, MD | None | ||
Jill Mattingly, DHSc, MMSc, PA-C | None | ||
Debra Newman, PA-C, MPAS, MPH | None | ||
| Mary McMasters, MD, DFASAM | None | ||
Yngvild K. Olsen, MD, MPH, DFASAM | None | ||
| Shawn Ryan, MD, MBA, FASAM | None | ||
| Kristin Smith, DNP, FNP-C, AAHIVS | None | ||
| Tricia E. Wright, MD, MS, FACOG, DFASAM | None | ||
ASAM CME Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
| Catherine Friedman, MD, FAPA, DFASAM, Chair | None | ||
| R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM | None | ||
| Adam J. Gordon, MD, MPH, FACP, DFASAM | None | ||
| Zwaantje Hamming, FNP-C, CARN-AP | None | ||
Herbert L. Malinoff, MD, FACP, DFASAM | None | ||
Noel Ilogu, MD, MRCP, DFASAM | None | ||
Edwin A. Salsitz, MD, DFASAM | None | ||
ASAM Staff and Consultants | |||
| Arlene C. Deverman, MA, CAE, CFRE | None | ||
Marcia Jackson, PhD | None | ||
| Sandy Metcalfe | None | ||
ASAM Medical Education Council
Name | Nature of Relevant Financial Relationship | |||
Commercial Interest | What was received? | For what role? | ||
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair | Pfizer Johnson & Johnson Pfizer Canada | Grant funding Consulting Fees Consulting Fees | Principal Investigator Consulting Consulting | |
| Daniel P. Alford, MD, MPH, DFASAM | None | |||
| Michael Fingerhood, MD, FACP, FASAM | None | |||
| Catherine R. Friedman, MD, FAPA, DFASAM | None | |||
| Adam J. Gordon, MD, MPH, FACP, DFASAM | None | |||
| Miriam S. Komaromy, MD, FACP, DFASAM | None | |||
| Edwin A. Salsitz, MD, DFASAM | None | |||
| Mark P. Schwartz, MD, DFASAM | None | |||
| Mark A. Weiner, MD, FASAM | None | |||
| ASAM Staff and Consultants | ||||
| Penny S. Mills, MBA | None | |||
| Arlene C. Deverman, MA, CAE, CFRE | None | |||
| Marcia Jackson, PhD | None | |||
| Dawn C. Howell | None | |||
| Molly S. Mazuk | None | |||
| Alexandra (Alli) Unger | None | |||
| Jennifer L. Butchart | None | |||
- Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
- Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
Edwin Salsitz
MD, DFASAM
Edwin Salsitz, MD, DFASAM has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.
Dr. Salsitz is Curriculum Director for The ASAM Treatment of Opioid Use Disorder Course and is a mentor in the PCSS-MAT mentoring program. He has co-chaired The ASAM Review Course, The ASAM Pain & Addiction: Common Threads Course, The ASAM State of the Art Course in Addiction Medicine and is a reviewer for the Journal of Addiction Medicine. He is the chair of The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives Course.
He is a member of the ASAM Medical Education Council and the ASAM CME Committee and is Chair of the New York Society of Addiction Medicine CME and Education Committees. Dr. Salsitz is a member of the medical advisory panel for the New York State Office of Alcohol and Substance Abuse Services. He is the recipient of the 2014 ASAM Annual Award and the 2018 ASAM Educator of the Year Award.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Key:
Complete
Next
Failed
Available
Locked